首页> 外文期刊>Antisense & Nucleic Acid Drug Development >Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent,FuGENE~TM6, in heLa cells
【24h】

Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent,FuGENE~TM6, in heLa cells

机译:转染试剂FuGENE〜TM6包裹的反义硫代磷酸酯寡核苷酸在heLa细胞中抑制人端粒酶活性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Telomerase,a ribonucleoprotein,synthesizes telomeric repeats (TTAGGG) onto the ends of chromosomes to maintain the constant length of the telomere DNA,and its activity is detectable in approximately 85%-90% of primary human cancers. Thus,it is postulated that human telomerase might be associated with malignant tumor development and could be a highly selective target for antitumor drug design.Antisense phosphorothioate oligonucleotides (S-ODN) were investigated for their abilities to inhibit telomerase activity in the HeLa cell line. The S-ODN were desinged to be complementary to nucleotides within the RNA active site of telomerase. As a transfection reagent,FuGENE~TM6(Boehringer Mannheim,Mannheim,Germany) was used to enhance the cellular uptake ofthe oligonucleotides in cell cultures.The S-ODN encapsulated with FuGENE~TM6 clearly inhibited telomerase activity in HeLa cells and showed sequence-specific inhibition.The encapsulated S-ODN-3 with a 19-nucleotide,(nt)chain length had inhibitory effects similar to those of the 21-mer and 23-mer S-ODN sequences (S-ODN-4 and 5), but the 15-mer and 17-mer S-ODN sequences (S-ODN-1 and 2)failed to satisfactorily prevent telomerase activity.However,apoptotic HeLa cell death was not associated with telomerase inhibition.Furthermore,the encapsulated S-ODN did not appear to be cytotoxic in terms of the cell growth rate.The oligonucleotides encapsulated with the transfection reagent had enhanced cellular uptake,and cytoplasmic and nuclear localizations were observed.However,weak fluorescent signals were observed within the cytoplasms of HeLa cells treated with the free S-ODN-3. Thus,the activities of the S-ODN were effectively enhanced by using the transfection reagent.The transfection reagent,FuGENE~TM6,maythus be a potentially useful delivery vehicle for oligonucleotide-based therapeutics and transgenes and is appropriate for use In vitro and In vivo.
机译:端粒酶是一种核糖核蛋白,可将端粒重复序列(TTAGGG)合成到染色体末端,以维持端粒DNA的恒定长度,其活性在大约85%-90%的原发性人类癌症中可检测到。因此,推测人类端粒酶可能与恶性肿瘤的发展有关,并且可能是抗肿瘤药物设计的高度选择性目标。研究了反义硫代磷酸酯寡核苷酸(S-ODN)在HeLa细胞系中抑制端粒酶活性的能力。希望将S-ODN与端粒酶的RNA活性位点内的核苷酸互补。 FugenE〜TM6(Boehringer Mannheim,Mannheim,Germany)作为转染试剂用于增强细胞培养物中寡核苷酸的细胞摄取.FuGENE〜TM6包裹的S-ODN明显抑制HeLa细胞中的端粒酶活性并显示序列特异性具有19个核苷酸,(nt)链长的S-ODN-3胶囊具有与21-mer和23-mer S-ODN序列(S-ODN-4和5)相似的抑制作用,但15聚体和17聚体的S-ODN序列(S-ODN-1和2)未能令人满意地阻止端粒酶活性。然而,凋亡的HeLa细胞死亡与端粒酶抑制无关。转染试剂包裹的寡核苷酸具有增强的细胞摄取能力,并观察到细胞质和细胞核定位。然而,用游离S处理的HeLa细胞的细胞质内却观察到微弱的荧光信号。 -ODN-3。因此,通过使用转染试剂可以有效地增强S-ODN的活性。转染试剂FuGENE〜TM6可能是基于寡核苷酸的治疗剂和转基因的潜在有用载体,并且适合在体内和体外使用。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号